INTERCEPT Pathogen-Reduced Plasma
Reduce Patient Risk of Transfusion Transmitted InfectionWhat is INTERCEPT Plasma?
The INTERCEPT Blood System for Plasma, pathogen reduction system, provides broad-spectrum reduction of pathogens and leukocytes, reducing the risks of transfusion-transmitted infection (TTI) from known and certain emerging pathogens, as well as transfusion-associated graft-versus-host disease (TA GvHD). INTERCEPT-treated plasma has a proven track record of safety and has demonstrated equivalent therapeutic efficacy to conventional plasma in clinical trials. Furthermore, the INTERCEPT treatment for plasma and platelets can occur on the same Illuminator platform for optimal efficiency.
Broad spectrum of pathogens inactivated by the INTERCEPT Blood System for Plasma1
GRAM-NEGATIVE BACTERIA
Klebsiella pneumoniae
Yersinia enterocolitica
Pseudomonas aeruginosa
Enterobacter cloacae
Anaplasma phagocytophilum
GRAM-POSTIVE BACTERIA
Staphylococcus epidermidis
Staphylococcus aureus
ENVELOPED and
NON-ENVELOPED VIRUSES
HIV-1
DHBV (model for HBV)
BVDV (Model for HCV)
HTLV-I
HTLV-II
WNV
Chikungunya
Influenza A
SARS-Associated Coronavirus
Parvovirus B-19
Bluetongue Virus
Adenovirus
PROTOZOA
Trypanosoma cruzi
Plasmodium falciparum
Babesia microti
SPIROCHETES
Treponema pallidum
Borrelia burgdorferi
LEUKOCYTES
Human T-Cells
There is no pathogen inactivation process that has been shown to eliminate all pathogens. Certain non-enveloped viruses (e.g., HAV, HEV, B19 and poliovirus) and Bacillus cereus spores have demonstrated resistance to the INTERCEPT process. For a full list of pathogens, please refer to package inserts.
1. INTERCEPT Blood System for Plasma [Package Insert]. Concord, CA: Cerus Corporation.